The company offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms. Teva combines scale in generics with branded specialty pharmaceuticals including COPAXONE for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for movement disorders.
Cyborg Score Rationale
Teva reported annual revenue of US$17.26b with net income of US$1.41b and achieved a past 3 months total return of 25.97%. However, the shares trade at a 28x P/E above industry averages, suggesting investors are paying a premium for execution and growth that involve risk.
Top Insights
Market cap has increased by 63.93% in one year, reflecting strong investor confidence
Recent Street research centers on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme
Competes with major players including AbbVie, Pfizer, Dr. Reddy's, and Roche
Has collaboration agreements with MedinCell S.A., Sanofi, Alvotech, and Biolojic Design Ltd.
Named Competitors
Generic Pharmaceuticals & Specialty — Diversified biopharmaceutical company
Pharmaceuticals — Integrated global pharmaceutical company
Generic Pharmaceuticals — Indian generic and specialty pharma producer
Diversified Pharma — Swiss healthcare and diagnostics conglomerate
Recent Developments
(March 2026) Market cap increased 63.93% over one year amid focused R&D pipeline initiatives
(February 2026) TTM revenue of $17.25B with net income of $1.41B, showing year-over-year growth
(September 2025) Investment in Cellyrix Therapeutics seed round as part of growth strategy
Open the full interactive Teva Pharmaceutical Industries Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.